Date: 24th May 2022
Location: Foster City Crowne Plaza, San Francisco
Attendee: David Cerny
Read more about Northern California Regional Chapter Spring Symposium 2022 Rise to the Next Normal
Date: 24th May 2022
Location: Foster City Crowne Plaza, San Francisco
Attendee: David Cerny
Read more about Northern California Regional Chapter Spring Symposium 2022 Rise to the Next Normal
Date: 12 - 13 May 2022
Location: Wequassett Resort & Golf Club in Chatham, MA on Cape Cod
Attending: Jon Gunther, Cenk Cetin
Evotec will be sponsoring the Convergence Forum 2022. Our Vice President Business Development, Just – Evotec Biologics, Jon Gunther, will be a speaker on "The bright future of biologics: How design & manufacturing can drive innovation, lower costs & broaden access" on Friday 13th May at 10:15am in mainstage session: How New Pressures are Changing Biopharma Manufacturing.
If you wish to meet with our experts at Convergence, get in touch via the form below, we will be happy to arrange a meeting.
Tags: Events, Evotec, Just Evotec Biologics
Autotaxin (ATX) is a secreted glycoprotein that hydrolyzes lysophosphatidylcholine (LPC) to lysophosphatidic acid (LPA). LPA signalling directly modulates tumour cell function and contributes to the development of the fibrotic tumour microenvironment, resulting in reduced host immunity and impaired response to therapy.
iOnctura, a clinical-stage oncology company, based in Switzerland (Genève), targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, has developed a potent and orally available autotaxin inhibitor, IOA-289, as a novel treatment for pancreatic cancer and other highly fibrotic tumours.
The first Phase I clinical study in healthy volunteers has been successfully completed. Evotec is very proud to have actively contributed in conducting the trial and analyzing the results that led to the achievement of this exciting goal.
Read the poster presented by iOnctura at the ESMO Immuno-Oncology Congress held in December 2021 to learn more about IOA-289 and its activity as autotaxin inhibitor. IOA-289 was also presented by iOnctura at the recently held AACR Annual Meeting in New Orleans.
Tags: Oncology, Posters, Clinical Development
Date: 23 June 2022
‘Advancing Data Technologies to Corner AMR’ unlocks the potential of AI, IOT and Blockchain in fighting AMR.
Join Evotec at the ADCTA 2022 in June!
Learn more about the Advancing Data Technologies to Corner AMR.
Date: 16-20 May 2022
Location: Oxford, Alderly Park and Edinburgh, UK
Attending: Pia Thomas, Alastaire Parkes, Kirsty Holden
Our scientific program
Collaborating to drive promising antibacterial programs towards the clinic
Monday, May 16th | Oxford
Working together to combat AMR
Wednesday, May 18th | Alderly Park
If you wish to meet with us, get in touch via the form below, we will be happy to arrange a meeting.
Date: 8th-9th June 2022
Location: Congress Center Basel, Switzerland
Attendees: Rob Brown, Frederic Somny
Evotec will be exhibiting at BOS Basel, back in person this year. You can meet our experts at booth # 41 and discuss about your project needs in discovery and in the small molecules and biologics integrated CMC areas.
If you wish to meet with us in Basel or outside of the event, get in touch via the form below, we will be happy to arrange a meeting.
The dispensation of compounds in aqueous or DMSO solutions is an integral part of Evotec’s sample management processes. The company has the capability for the automated array of large numbers of samples between a large variety of different containers suitable for both, distribution or storage. Its extensive liquid handling resources cover the widest range of possible volumes.
High-volume systems can dispense and transfer from 1 uL to multi-milliliters to and from vials and plates, while mid-volume systems can dispense from 1 uL to 2 mL using 96, 384 and 1536 plates or racks (SBS - Society for Biomolecular Screening – formats).
As Evotec is striving towards the goal of getting drugs to patients faster, it is constantly seeking to improve the speed of screening cycles and data quality. To enable a step change in drug discovery research and development and to obtain results faster and even more accurately with very small sample sizes, Evotec recently invested in the so-called Acoustic Tubes technology in partnership with Brooks, Beckman and Titian. Acoustic sampling has revolutionised liquid handling and Evotec is using two different systems for acoustically dispensing volumes over 1 uL, or between 2.5 nl and 1 µl.
The technology is using ultrasonic acoustic energy, where energy focused just below the meniscus of a liquid sample ejects small droplets of liquid, enabling very small volumes to be transferred from source wells and precisely positioned onto a destination surface suspended above the ejection point. As a result, scientists can do more with less, handling multiple workflows and generating faster results without the restrictions of traditional tip-based liquid handling.
Moreover, this acoustic technology is combined with newly designed caps, a new de-capping and recapping technology hence creating the ability to store and access compounds long-term directly from the same tubes.
To evaluate the effects of acoustic labware use for long and short-term storage as well as the impact of freeze/thaw cycles and acoustic dispensing on compound integrity, Evotec has completed rigorous testing of the technology before adopting it.
The technology has a number of benefits. Most importantly, it speeds up screening cycles and improves the capacity for cherry-picking plate creation. Besides minimising compound consumption, it also works without disposable tips. This reduces waste, operating costs and eliminates the risk of cross-contamination between compounds. Moreover, its precision and speed leads to unsurpassed accuracy and repeatability of results, while maintaining sample integrity and viability during the transfer. All in all, it saves time, cost and resources, provides for highest possible precision, and increases the flexibility in transferring liquids at different positions and volumes.
Adoption of acoustic sampling technologies increases the flexibility of the compound library at Evotec and its partners and speeds up the throughput for assay-ready plate preparation while reducing the consumption of compounds. Evotec is offering direct access to this technology to its customers on demand.
Tags: Blog, Sample Management